As described above, the AurkA/TPX2 complex is overexpressed in several tumour types (breast, lung, prostate, ovarian, and others) and contributes to aneuploidy as well as CIN, favouring tumour heterogeneity and drug resistance. Here, TPX2 is linked to neoplasm.